Lower limb ulcers were outlined in nine trials (4, 1, 2, and 2 with canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, respectively) for a total of 305 events with SGLT2-is versus 181 events with comparators, thus resulting in a global RRMH of 1.39 [1.01–1.91] (Figure 5). Here, SLC5A2 is linked to ulcer of lower limb.